Literature DB >> 12472763

Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy.

William G Goodman1, Harald Jüppner, Isidro B Salusky, Donald J Sherrard.   

Abstract

Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Reliable measurements of parathyroid hormone (PTH) concentrations in serum or plasma are critical for the appropriate diagnosis and management of patients with renal osteodystrophy. With the introduction of second generation immunometric assays for PTH, it is now possible to measure exclusively full-length, biologically active PTH(1-84). In contrast, first generation immunometric assays that have been used widely for many years detect not only PTH(1-84), but also other large amino-terminally-truncated, PTH-derived peptides. This development will require a careful re-evaluation of PTH measurements, as determined by either first or second generation immunometric assays, and their relationship to bone histology and bone remodeling rates in patients with end-stage renal disease (ESRD). Such information is essential for proper clinical management, but only limited bone biopsy data are available to guide the interpretation of PTH results using second generation PTH assays. The different performance characteristics of first and second generation immunometric PTH assays also makes it possible to quantify the plasma levels of amino-terminally-truncated, PTH-derived peptides, which may accumulate disproportionately in patients with ESRD. Recent experimental evidence indicates that one or more of these peptides can modify bone cell activity and skeletal remodeling, possibly by interacting with a PTH receptor distinct from the type I PTH receptor that binds to the amino-terminal portion of PTH and mediates the classical biological actions of the hormone. The putative C-PTH receptor interacts with mid- and/or carboxyterminal regions of PTH and other amino-terminally-truncated PTH-derived peptides; signaling through it may contribute to the skeletal resistance to PTH that characterizes ESRD. The current review discusses certain aspects of the molecular structure of PTH and its interaction with various receptors, briefly comments about selected components of PTH secretion, highlights recent technical advances in PTH assays, and summarizes the effects of various PTH-derived peptides on bone cells and on skeletal metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12472763     DOI: 10.1046/j.1523-1755.2003.00700.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Expression of bone type 1 PTH receptor in rats with chronic renal failure.

Authors:  Michio Kuwahara; Seiji Inoshita; Yukiko Nakano; Yoshio Terada; Yoshiro Takano; Sei Sasaki
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

2.  Differences between "intact" PTH and 1-84 PTH assays in chronic renal failure and dialysis.

Authors:  Simon Waller; Deborah Ridout; Tom Cantor; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2004-12-31       Impact factor: 3.714

3.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.

Authors:  Takashi Shimada; Itaru Urakawa; Tamara Isakova; Yuji Yamazaki; Michael Epstein; Katherine Wesseling-Perry; Myles Wolf; Isidro B Salusky; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

4.  Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review.

Authors:  Hirotaka Komaba; Yoko Takeda; Jeongsoo Shin; Reika Tanaka; Takatoshi Kakuta; Yoshihiro Tominaga; Masafumi Fukagawa
Journal:  NDT Plus       Date:  2008-08

5.  International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data.

Authors:  Elizabeth Hedgeman; Loren Lipworth; Kimberly Lowe; Rajiv Saran; Thy Do; Jon Fryzek
Journal:  Int J Nephrol       Date:  2015-03-31

6.  Parathyroid hormone assay: problems and opportunities.

Authors:  Kevin J Martin; Esther A González
Journal:  Pediatr Nephrol       Date:  2007-05-22       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.